These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36125060)

  • 1. Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States.
    Mendola ND; Oehrlein E; Perfetto EM; Westrich K; McQueen RB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1190-1196. PubMed ID: 36125060
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.
    Campolina AG; Estevez-Diz MDP; Abe JM; de Soárez PC
    PLoS One; 2022; 17(5):e0268584. PubMed ID: 35613115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.
    Angelis A; Thursz M; Ratziu V; O'Brien A; Serfaty L; Canbay A; Schiefke I; Costa JBE; Lecomte P; Kanavos P
    Med Decis Making; 2020 Aug; 40(6):830-845. PubMed ID: 32845234
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicriteria decision analysis in health care decision in oncology: a systematic review.
    Campolina AG; Suzumura EA; Hong QN; de Soárez PC
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):365-380. PubMed ID: 34913775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.
    Hoshikawa K; Ono S
    J Clin Pharm Ther; 2017 Feb; 42(1):80-86. PubMed ID: 27914099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
    Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
    Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
    Baltussen R; Marsh K; Thokala P; Diaby V; Castro H; Cleemput I; Garau M; Iskrov G; Olyaeemanesh A; Mirelman A; Mobinizadeh M; Morton A; Tringali M; van Til J; Valentim J; Wagner M; Youngkong S; Zah V; Toll A; Jansen M; Bijlmakers L; Oortwijn W; Broekhuizen H
    Value Health; 2019 Nov; 22(11):1283-1288. PubMed ID: 31708065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.
    Goetghebeur MM; Wagner M; Khoury H; Rindress D; Grégoire JP; Deal C
    Cost Eff Resour Alloc; 2010 Apr; 8():4. PubMed ID: 20377888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
    Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
    Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.